Skip to content
Kalpvruksh Markets
Offline Log in

CAPLIPOINTNSEOffline

CAPLIN POINT LAB · INE475E01026 · Small Cap · #460
2,421.40+5.30 (+0.22%)last close · 05 Nov 2026
Prev close
2,416.10
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹14,145 cr
52-week range · to 05 Nov 20261,504.82,867.4

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

CAPLIPOINT is 16% below its 52-week high, above its 200-day average, behind Healthcare by 5.6 pts over 3 months — a Small Cap company, #460 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 200-day averages · below its 50-day average · 16% below its 52-week high
  • behind its industry by 5.6 pts over 3 months · rank 23 of 44 in Healthcare · −2.6% vs Nifty 500
  • traded value 0.6× usual · delivery 55% vs 42% usual
  • FPI −0.0 pp · DII −0.3 pp · MF schemes in Sept 2026: 21 bought, 30 cut · no promoter pledge · quarter ended 2026-09-30
  • Jun 2026 quarter: profit +16% year on year · revenue +20%
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹14,145 cr
Rank
#460
Cap band
Small Cap
Nearest cut-off — Mid / Small
−58.63% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
0.9×
median 41,842
Delivered
35,958
Of volume
58%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+1.9%−3.7 pts—
1 month−9.6%−13.6 pts−13.1 pts
3 months−4.7%−2.6 pts−5.6 pts
6 months+31.5%+31.0 pts+18.6 pts
1 year+19.3%+22.4 pts—

Industry: Healthcare (Nifty 500 classification) · rank 23 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+3.2%
above
vs 50-day average
−5.3%
below
vs 200-day average
+11.4%
above
ATR (14)
3.0%
typical daily range
Volatility
33%
1 month, annualised
Beta
0.91
vs Nifty 500, 1 year
Traded value
0.6×
vs usual
Delivery
55%
usual 42%
From the 52-week high
−15.6%
place in range 67% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters70.6%70.6%70.6%70.6%
FPI6.5%6.2% −0.45.8% −0.45.7%
Mutual funds2.0%2.0% +0.12.0%1.6% −0.4
Other DII0.1%0.1%0.5% +0.30.6% +0.1
Individuals14.1%14.5% +0.314.6% +0.214.9% +0.3
Others6.7%6.7%6.6% −0.16.6%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
1,03,386
Individuals
97,550

Indian passive funds’ stake

2026-06-30

Of free float
0.63%
Of all shares
0.19%
Schemes
48
Days to unwind
0.9
at 100% of volume

1,41,027 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
56
48 index · 8 active
Bought more
32
Sold some
18
FundSharesChangeDid
UTI Healthcare Fund-Reg(IDCW)Active+55,000+37.9%bought
Nippon India Nifty Smallcap 250 Index Fund-Reg(G)Index+1,365+4.6%bought
Motilal Oswal Nifty Smallcap 250 Index Fund-Reg(G)Index+439+4.0%bought
ITI Pharma & Healthcare Fund-Reg(G)Active−4,765−45.6%sold
UTI Multi Cap Fund-Reg(G)Active−50,362−32.5%sold
Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETFIndex−4,068−19.4%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 2656417273−4.6%₹333 cr
Aug 265523691−9.3%₹323 cr
Jul 2654728113−6.2%₹356 cr
Jun 2650725160−4.5%₹396 cr
May 2643117140+2.7%₹320 cr
Apr 264222830+1.2%₹263 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    12 Aug 2026
  • Board outcome
    Outcome of Board Meeting-XBRL CAPLIN POINT LABORATORIES LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 12-Aug-2026 for Dividend
    12 Aug 2026

CAPLIPOINT: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
RecentDividend₹4Final18 Sept 202618 Sept 2026
EarlierDividend₹4Interim29 May 202630 May 2026
EarlierDividend₹3Final12 Sept 202512 Sept 2025
EarlierDividend₹3Interim30 May 202530 May 2025
EarlierDividend₹2.5Final23 Sept 202424 Sept 2024
EarlierDividend₹2.5Interim31 May 202431 May 2024
EarlierDividend₹2.5Final14 Sept 202315 Sept 2023
EarlierDividend₹2Interim09 Jun 202309 Jun 2023
EarlierDividend₹2Final21 Sept 202223 Sept 2022
EarlierDividend₹2Interim23 May 202224 May 2022

11 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.